Loading...
•
Dec 31, 2021
Intra-Cellular Q4 2021 Earnings Report
Intra-Cellular Therapies reported a strong fourth quarter and full-year 2021, highlighted by FDA approval for CAPLYTA® in bipolar depression and a 106% increase in total revenues for the quarter.
Key Takeaways
Intra-Cellular Therapies announced its Q4 and full-year 2021 financial results, marked by FDA approval of CAPLYTA for bipolar depression and significant revenue growth. Total Q4 revenues reached $25.7 million, a 106% increase year-over-year, with CAPLYTA net product revenues at $25.5 million, also a 106% increase. The company is advancing CAPLYTA development programs and other pipeline initiatives.
Received FDA approval for CAPLYTA for the treatment of bipolar depression in adults.
Total revenues for the fourth quarter increased by 106% to $25.7 million compared to the same period in 2020.
CAPLYTA net product revenues for the fourth quarter increased by 106% to $25.5 million compared to the same period in 2020.
CAPLYTA total prescriptions increased 15% versus the previous quarter and 98% versus the same period in 2020.
Intra-Cellular
Intra-Cellular
Forward Guidance
Intra-Cellular Therapies is focused on maximizing CAPLYTA’s potential with continued progress in late-stage programs in MDD and additional mood disorders to help more patients with major neuropsychiatric conditions. In addition, the company is continuing to advance other pipeline programs.
Positive Outlook
- Continued progress in late-stage programs in MDD.
- Advancing programs in additional mood disorders.
- Helping more patients with major neuropsychiatric conditions.
- Continuing to advance other pipeline programs.
- Expecting to commence clinical conduct in AD agitation program in 2022.
Challenges Ahead
- There are no guarantees that CAPLYTA will be commercially successful.
- The COVID-19 pandemic may negatively impact commercial plans and sales for CAPLYTA.
- Results achieved in CAPLYTA in the treatment of schizophrenia and bipolar depression following commercial launch of the product may be different than observed in clinical trials, and may vary among patients.
- We may encounter unexpected safety or tolerability issues with CAPLYTA following commercial launch for the treatment of schizophrenia or bipolar depression or in ongoing or future trials and other development activities.
- Our reliance on collaborative partners and other third parties for development of our product candidates.